Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Sees Large Decline in Short Interest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totalling 240,400 shares, a decrease of 37.8% from the November 30th total of 386,500 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average daily volume of 3,380,000 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reissued a “hold” rating on shares of Virpax Pharmaceuticals in a research note on Wednesday, October 9th.

Institutional Trading of Virpax Pharmaceuticals

A hedge fund recently bought a new stake in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC bought a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals at the end of the most recent quarter. Institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Price Performance

VRPX opened at $0.41 on Friday. Virpax Pharmaceuticals has a fifty-two week low of $0.29 and a fifty-two week high of $5.48. The company’s 50 day moving average price is $0.52 and its two-hundred day moving average price is $0.74.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.